Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SDH-Combi
- Development stage
- Phase 1
- Lead developer
- Seoul Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SDH-Combi is an experimental combination cellular immunotherapy comprising Natural Killer (NK) cells and Cytotoxic T Lymphocytes (CTLs). Developed by Seoul Hospital, this biological therapy is designed to treat refractory metastatic solid tumors, specifically adenocarcinomas. The treatment strategy leverages the synergistic effects of the innate immune system (NK cells) and the adaptive immune system (CTLs) to target and eliminate cancer cells that have become resistant to standard-of-care therapies. NK cells provide rapid, non-MHC-restricted anti-tumor activity, while CTLs provide antigen-specific targeting. It is currently being evaluated in Phase 1 clinical trials for safety and preliminary efficacy in patients with Stage IV solid tumors.
- Other names
- Combi-Seoul HospitalNK cells and CTLs combination therapy
Beyond the preview
Go deeper on SDH-Combi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SDH-Combi.